Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

ESMO Open · 2025 · PMC12414892 · PMID 40882246

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

reported that melanoma patients who developed autoantibodies showed a trend for better survival, whereas a link between irAE occurrence and clinical outcome was not observed. 38 In our prospective study as part of the TITAN-RCC trial, 33 we did not observe a significant association between pre-existing autoantibodies and achieved disease control.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.